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Abstract
Background: Skeletal-muscle differentiation is required for the regeneration of myofibers after injury. The
differentiation capacity of satellite cells is impaired in settings of old age, which is at least one factor in the onset
of sarcopenia, the age-related loss of skeletal-muscle mass and major cause of frailty. One important cause of
impaired regeneration is increased levels of transforming growth factor (TGF)-b accompanied by reduced Notch
signaling. Pro-inflammatory cytokines are also upregulated in aging, which led us hypothesize that they might
potentially contribute to impaired regeneration in sarcopenia. Thus, in this study, we further analyzed the muscle
differentiation-inhibition pathway mediated by pro-inflammatory cytokines in human skeletal muscle cells
(HuSKMCs).
Methods: We studied the modulation of HuSKMC differentiation by the pro-inflammatory cytokines interleukin (IL)-
1a and tumor necrosis factor (TNF)-a The grade of differentiation was determined by either imaging (fusion index)
or creatine kinase (CK) activity, a marker of muscle differentiation. Secretion of TGF-b proteins during differentiation
was assessed by using a TGF-b-responsive reporter-gene assay and further identified by means of pharmacological
and genetic inhibitors. In addition, signaling events were monitored by western blotting and reverse transcription
PCR, both in HuSKMC cultures and in samples from a rat sarcopenia study.
Results: The pro-inflammatory cytokines IL-1a and TNF-a block differentiation of human myoblasts into myotubes.
This anti-differentiation effect requires activation of TGF-b-activated kinase (TAK)-1. Using pharmacological and
genetic inhibitors, the TAK-1 pathway could be traced to p38 and NFB. Surprisingly, the anti-differentiation effect
of the cytokines required the transcriptional upregulation of Activin A, which in turn acted through its established
signaling pathway: ActRII/ALK/SMAD. Inhibition of Activin A signaling was able to rescue human myoblasts treated
with IL-1b or TNF-a, resulting in normal differentiation into myotubes. Studies in aged rats as a model of
sarcopenia confirmed that this pro-inflammatory cytokine pathway identified is activated during aging.
Conclusions: In this study, we found an unexpected connection between cytokine and Activin signaling, revealing
a new mechanism by which cytokines affect skeletal muscle, and establishing the physiologic relevance of this
pathway in the impaired regeneration seen in sarcopenia.
Background
Regeneration of myofibers after injury requires skeletal-
muscle differentiation [1,2]. It has been shown in studies
of old age that the differentiation capacity of satellite
cells is impaired, which is at least one factor in the
onset of sarcopenia, the age-related loss of skeletal-mus-
cle mass and strength [3]. Myoblast differentiation is
influenced by a number of factors. For example, insulin-
like growth factor (IGF)-1 and low serum conditions
promote differentiation [4-6], whereas transforming
growth factor (TGF)-b and its family members, such as
myostatin, block differentiation [7-13] as do pro-inflam-
matory cytokines [14-16].
The role of the pro-inflammatory cytokines, particularly
in skeletal-muscle differentiation, is controversial, as there
are conflicting reports, documenting the capacity of these
cytokines to either induce [17-19] or inhibit [14-16,19] dif-
ferentiation. Tumor necrosis factor (TNF)-a was found to
be required for myogenesis, as shown by impaired regen-
eration in TNF-a null animals [20]; however, the
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tion is apparently very low, and higher levels can have the
opposite effect; for example, whereas 0.05 ng/ml of TNF-a
stimulated myogenesis, 0.5 and 5 ng/ml caused inhibition
[19]. Similarly, the role of the downstream p38 pathway is
under some dispute. On the one hand, the activity of p38
mitogen-activated protein kinase (MAPK) is reportedly
increased during myogenesis, and its inhibition was shown
to inhibit the expression of select muscle-specific genes
and formation of multinucleated myotubes [21]. During
myogenesis, the activation of p38 MAPK promotes cell
cycle exit by inducing the expression of a cyclin-dependent
kinase inhibitor, p21, which facilitates terminal differentia-
tion of muscle precursor cells [22]. On the other hand,
however, there are multiple reports of p38 inhibiting myo-
genesis; for example, MAPK kinase kinase (MEKK)1 sig-
naling through p38 was shown to result in the inactivation
of E47 and thus repress myogenesis [23], and p38 phos-
phorylation of the transactivation domain of myogenic
regulatory factor (MRF)4 represses transcription of myo-
genic genes [24].
The phosphoinositide 3-kinase (PI3K)/AKT pathway is
also activated during myogenesis, and insulin-like
growth factor (IGF)-1, which initiates PI3K/AKT signal-
ing, is able to induce both differentiation of myoblasts
[5,6], and hypertrophy of post-differentiated myotubes
[25-29]. In post-differentiated muscle, IGF-1/PI3K/AKT
signaling opposes the action of TNF-a/NFB activity,
for example by inhibiting NFB-mediated upregulation
of the E3 ubiquitin ligases MuRF1 and MAFbx, which
are required for skeletal muscle atrophy [30].
TGF-b-activated kinase 1 (TAK-1), a member of the
MEKK (MAP3K) family, was identified as a regulator of
TGF-b-induced activation of MAPK [31]. Recent studies
have shown that TAK-1 is also a component of signal-
ing pathways leading to the activation of NFB and acti-
vator protein-1 in response to diverse cytokines,
including interleukin (IL)-1 and TNF-a [32-37]. How-
ever, the role of TAK-1 in muscle progenitor cells has
not been definitively determined, although a recent
study claimed that TAK-1 is essential for the differentia-
tion of myoblasts, and is required for the myogenic
actions of IGF-1 [38]. This was unexpected, because
TGF-b molecules themselves have been shown in multi-
ple studies to block muscle differentiation [13,39-41],
suggesting that TAK-1 is a negative modulator of mus-
cle differentiation. In the present study, we found that
TAK-1 connects TNF-a and IL-1 to Activin signaling,
explaining how these cytokines can inhibit myogenesis.
Methods
Cell culture and treatment
Human skeletal muscle cells (HuSKMCs; Lonza AG,
Basel, Switzerland) were cultured in growth medium
(GM) consisting of skeletal muscle basal medium
(skBM; Lonza) supplemented with 20% FCS (PAA
Laboratories, Dartmouth, PA, USA). Differentiation was
initiated 24 to 48 hours after seeding by changing to a
serum-free differentiation medium (DM), skBM. For
small interfering (si)RNA experiments, cells were trans-
fected 24 hours after seeding in GM, and differentiation
was initiated after another 24 hours.
To determine NFB activity, HuSKMCs were infected
24 hours after seeding with human recombinant adeno-
virus-NFB-luciferase (Vector Laboratories Inc., Burlin-
game, CA, USA) in GM for 48 hours, then the medium
was removed and the cells stimulated for another 6
hours in serum-free skBM with the compounds under
investigation To assess the effects on HuSKMC differen-
tiation, the assessed compounds were added at the onset
of differentiation, and cells were differentiated into myo-
tubes for up to 120 hours. To measure TGF-b reporter-
gene activity in supernatants ( S N s )f r o md i f f e r e n t i a t i n g
HuSKMCs, a reporter-gene assay (RGA) was used.
HEK293T cells stably transfected with pGL3-CAGA12-
luc were seeded in serum-reduced medium (2% FCS) for
24 hours, then the medium was removed, and the cells
stimulated with a 10:1 mixture of supernatant and
serum-enriched medium (20% FCS) in the absence or
presence of 500 ng/ml of a human Fc-TGF-b RIIb/Fc
chimera (TGF-bRIIb) alone or in combination with neu-
tralizing anti-Activin A antibody (aActA) for another 24
hours.
Biochemistry
The following reagents were used: human IL-1a), IL-1b,
TNF-a,T G F - bRIIb, andaActA (all R&D Systems Inc.,
Minneapolis, MN, USA), long-R3-iIGF-1, SB431542
(both Sigma-Aldrich, St Louis, MO, USA), SB203580,
withaferin A (both Tocris Bioscience, Ellsville, MO,
USA), and TAK-1 inhibitor (AnalytiCon Discovery AG,
Potsdam, Germany). Stock solutions were prepared
either in PBS supplemented with 0.1% BSA for Fc-TGF-
bRIIBb, TNF-a and IL-1a, in 10 mmol/l HCl for IGF-1
or in dimethyl sulfoxide (DMSO) for TAK-1 inhibitor,
SB431542, SB203580, and withaferin A. For immunos-
taining, a primary antibody against myosin heavy chain
(MyHC) was used (clone A4.1025; Upstate Biotechnol-
ogy, Lake Placid, NY, USA), and the secondary antibody
was conjugated to a fluorescent dye (Alexa Fluor
® 488 F
(AB’); Invitrogen Corp., Carlsbad, CA, USA).
Primary antibodies against phospho-TAK-1 (Thr 184/
187), phospho-SEK/MKK4 (Thr241), phospho-
p38MAPK (Thr 180/Tyr182), phospho-c-Jun (Ser63),
phospho-activating transcription factor (ATF)2 (Thr71),
phospho-NFB p65 (Ser536), phospho-SMAD2 (Ser465/
467), phospho-AKT (Ser473) (all Cell Signaling Tech-
nology, Beverly, MA, USA), and phospho-SMAD3
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used for western blotting. The loading control was a-
tubulin (Sigma), and the secondary antibodies were
labelled with horseradish peroxidase (HRP) (goat anti-
rabbit IgG HRP and goat anti-mouse IgG HRP; Cell Sig-
naling Technology).
Western blotting
Lysis buffer consisting of extraction reagent (Phosphosafe;
Novagen Inc., Madison, WI, USA) supplemented with 1%
protease inhibitor cocktail (Sigma-Aldrich) was added.
Homogenates were separated by centrifugation for 10
minutes at 4°C (14,000 rpm). Supernatants were collected
and protein contents measured a commercial kit for pro-
tein determination (BCA Kit; Sigma-Aldrich). Samples
were diluted in SDS-PAGE sample buffer and denatured
for 5 minutes at 95°C. Equal amounts of protein were
loaded per lane of 4 to 12% polyacrylamide gel (NuPAGE
Bis-Tris gel; Invitrogen Corp., Carlsbad, CA, USA), sepa-
rated by electrophoresis, and then transferred onto nitro-
cellulose membranes. Membranes were blocked in TBS
with 5% w/v non-fat milk powder. Primary antibodies
were incubated in TBS with 0.1% Tween 20 and 5% BSA
with the exception of phospho-SMAD2 (incubated with
5% non-fat milk), and secondary antibodies in TBS with
0.1% Tween 20, 0.05% SDS and 5% non-fat milk. Immu-
noreactivity was detected by SuperSignal West Femto
Maximum Sensitivity Substrate and exposed to film.
RNA analysis
RNA was isolated using commercial kits (RNEasy Mini
Kit, RNEasy MinElute Kit and RNase-Free DNase Set;
Qiagen Inc., Valencia, CA, USA), following the manufac-
turer’s protocol. Samples were prepared for reverse tran-
scription PCR (QuantiFAST Multiplex RT-PCR+R Kit;
Qiagen Inc.) and run in an automated PCR machine
(7500 FAST Real-time PCR machine; Applied Biosys-
tems, Foster City, CA, USA). A TaqMan probe set for
the Activin A b-chain was used (Inhibin b A;
Rn00567500_m1: rat; Hs01081598_m1: human; Applied
Biosystems, Foster City, CA, USA).
Small interfering RNA
T h es i R N Ap o o l su s e dw e r ed e s i g n e da g a i n s tS M A D 2 ,
SMAD3, the Activin A b-chain (Inhibin b A), and a
non-targeting control (NTC) targeting an unknown
mammalian sequence together with transfection reagent
(DharmaFECT 1; Dharmacon/Thermo Fisher Scientific
I n c . ,R o c k f o r d ,I L ,U S A )w e r eu s e d ,t og i v eaf i n a l
siRNA concentration of 100 nmol/L.
Immunostaining
After washing with cytoskeleton stabilizing buffer (CSB;
80 mmol/l PIPES, 5 mmol/l EGTA, 1 mmol/l MgCl2,4 0
g/l PEG3500 in distilled water at pH7.4), cells were
fixed with 4% paraformaldehyde in CSB. Cells were then
permeabilized with 0.2% Triton in CSB, and non-specific
binding blocked with normal goat serum (Zymed
Laboratories Inc., South San Francisco, CA, USA) fol-
lowed by incubation with MyHC diluted in PBS and
subsequently with fluorescent dye (Alexa Fluor
® 488 F
(AB’); Invitrogen Corp.) diluted in PBS. Cells wre
mounted with in an antifade reagent with DAPI (Pro-
Long Gold; Invitrogen Corp.).
Reporter-gene assays
HEK293T cells stably transfected with the TGF-b
responsive construct CAGA12-luc cloned into the
reporter construct pGL3 (Promega Corp., Madison, WI,
USA) were kindly provided by C. Lu (Developmental
and Molecular Pathways, Novartis Pharma AG, Basel,
Switzerland). Infection of HuSKMCs was performed
using the human recombinant adenovirus-NFB-lucifer-
ase reporter (Vector Laboratories Inc., Burlingame, CA,
USA). Reporter-gene activity was measured using Brite-
lite Plus (Perkin Elmer, Waltham, MA, USA), and che-
miluminescence was read using a spectrophotometer
(Spectramax M5; Molecular Devices Inc., Sunnyvale,
CA, USA).
Creatine kinase activity assay
Cells were washed three times with PBS and then lysed
with reporter lysis buffer (Promega Corp.) and stored at
-80°C until measurement. Creatinine kinase (CK) activity
was measured using a commercial reagent (CK (IFCC)
Reagent; Thermo Electron, Waltham, MA, USA), pre-
pared according to the manufacturer’s instructions.
Lysates were adjusted to room temperature, CK reagent
was added, and absorbance was immediately read at 340
nm for 20 minutes with a reading interval of 1 minute.
CK standard curves were freshly prepared using CK
from rabbit muscle (Roche Diagnostics, Basel, Switzer-
land). Protein content was determined using a commer-
cial (BCA Kit; Sigma-Aldrich), as before.
Activin A ELISA
ELISA for Activin A (Human Activin A DuoSet; R&D
Systems Inc.) was performed according to the manufac-
turer’s instructions, using a modified chemiluminescent
measurement. Briefly, plates were coated with capture
antibodies overnight at 4°C, and non-specific binding
was blocked with PBS plus 1% BSA for at least 1 hour.
Supernatants and 6M Urea (1:1) were added and incu-
bated for 2 hours at room temperature. Detection anti-
body was added for 2 hours at room temperature
followed by incubation with HRP-labeled streptavidin
for 20 minutes at room temperature. After addition of a
chemiluminescent substrate (SuperSignal ELISA Femto
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Inc., Rockford, Illinois, USA) chemiluminescence was
read using a spectrophotometer (Spectramax M5; Mole-
cular Devices Inc.).
In vivo experiments
All animal procedures were approved by the cantonal
veterinarian office of Basel (license number 2127).
Male Wistar rats (Janvier, Le Genest Saint Isle,
France) of various ages (4 per group) were housed for 2
weeks on a 12 hour light/dark cycle with unrestricted
access to food and water. Rats were asphyxiated using
CO2 at 6, 18, 21 and 24 months (29, 81, 93 and 106
weeks) of age, and the gastrocnemius muscle was imme-
diately dissected, weighed and snap-frozen in liquid
nitrogen before processing for RNA extraction. Com-
pared with 6-month-old rats, the gastrocnemius weight
was unchanged for 18-month-old rats and reduced by
41% and 49% in 21- and 24-month-old rats, respectively.
Statistical analysis
Differences between groups were analyzed using one-
way ANOVA for all experiments. P < 0.05 was consid-
ered significant.
Results and discussion
The transforming growth factor-b/SMAD and insulin-like
growth factor-1/AKT pathways modulate interleukin-1a-
and tumor necrosis factor-a-induced inhibition of human
skeletal myoblast differentiation
In this study, we were interested in determining the
effect of cytokines on human skeletal myoblast differen-
tiation. As a first step, it was important to characterize
whether HuSKMCs [13] respond to cytokines in a simi-
lar manner to myoblast lines from other species. We
used IL-1a to stimulate IL-1 receptors throughout this
study, but very similar effects were seen whenever IL-1b
was tested as well (data not shown). HuSKMCs were
differentiated in the absence or presence of IL-1a and
TNF-a for 5 days after the onset of differentiation, and
immunostained with antibodies to MyHC as a marker
for differentiation (Figure 1A, left panel). Similar to pre-
vious studies, both IL-1a and TNF-a caused a marked
reduction in HuSKMC differentiation, seen as a decrease
in both myotube number (Figure 1A, left panel) and
fusion index (FI), which were decreased by 73% with IL-
1a and by 55% witu TNF-a (Figure 1A, right panel).
Moreover, CK activity, which normally increases during
differentiation, was also markedly reduced by IL-1a and
TNF-a (Figure 1B); no increase in CK activity was seen
at any concentration tested (0.001 to 1 ng/ml; data not
shown).
We next investigated whether the anti-differentiation
effect of IL-1a and TNF-a on HuSKMCs is perturbed by
IGF-1, a positive regulator of myogenesis. Treatment with
IGF-1 promoted basal differentiation of HuSKMCs by up
to 77%, and partially rescued them from the inhibitory
effects of IL-1a and TNF-a, as determined by FI (Figure
1A, right panel) and CK activity (Figure 1B). Because IGF-
1-mediated AKT signaling has been shown to block the
inhibition of differentiation caused by TGF-b family mem-
bers [13], we investigated whether the intersection
between cytokine signaling and IGF-1 signaling might
involve the TGF-b pathway. Therefore we sought to deter-
mine the influence of the TGF-b/ALK pathway in IL-1a
and TNF-a action, using the ALK4/5/7 inhibitor
SB431542. Treatment with SB431542 promoted basal
HuSKMC differentiation by up to threefold and partially
rescued the blocking of differentiation caused by IL-1a
and TNF-a, analyzed by either FI (Figure 1A, right panel)
or CK activity (Figure 1B) suggesting that TGF-b/ALK sig-
n a l i n gm a yp l a yar o l ei nt h eI L - 1 a and TNF-a-induced
inhibition of HuSKMC differentiation.
Interleukin-1a and tumor necrosis factor-a induce
secretion of Activin A via activation of the transforming
growth factor-b-activated kinase (TAK)-1/p38/nuclear
factor B pathway during human skeletal muscle cells
differentiation; secretion is independent of SMAD2/3
T h ef a c tt h a tt h ea n t i - m y o g e n e s i se f f e c t so fI L - 1 a and
TNF-a could be blocked using an ALK inhibitor sug-
gested either that these two pathways were acting in
parallel, and that the ALK inhibitor simply perturbed
the basal tone of differentiation, or that there could be
an increase in activation of the TGF-b receptor/ALK
pathway upon cytokine treatment. This might occur via
an increase in the production and subsequent secretion
of TGF-b family-member proteins. We therefore sought
to determine if TGF-b protein secretion from differen-
tiating HuSKMCs contributes to the IL-1a and TNF-a
inhibition of myogenesis. Supernatants from HuSKMCs
differentiated in the absence and presence of IL-1a and
TNF-a were analyzed in an RGA, using as activity mar-
ker CAGA-luc (a luciferase reporter for SMAD2/3 tran-
scription factor), which is sensitive to most TGF-b
proteins including the TGF-b isoforms TGF-b1, TGF-b2
and TGF-b3, the activins, myostatin, and growth differ-
entiation factor (GDF)-11.
Supernatants from untreated HuSKMCs induced a
small degree of SMAD2/3 CAGA-luc activity (Figure
2A), confirming autocrine secretion of active TGF-b
proteins from differentiating HuSKMCs.
We next determined which TGF-b family-member
proteins are secreted from HuSKMCs by adding phar-
macologic inhibitors to the supernatant. In supernatant
from untreated HuSKMCs, SMAD2/3 activity mainly
represents TGF-b isoforms, as indicated by the marked
reduction of SMAD2/3 CAGA-luc activity (by about
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2A, TGF-bRIIb) was added to the supernatant, and the
lack of further reduction after addition of either a neu-
tralizing Activin A antibody (Figure 2A, aActA) or fol-
listatin (a natural blocker of myostatin; data not shown),
GDF-11, and activins. Supernatants harvested from
HuSKMCs showed markedly increased CAGA-luc activ-
ity after treatment with IL-1a and TNF-a,w i t h
increases of 776% and 711%, respectively *Figure 2A).
Addition of TGF-bRIIb to the supernatant did not
change SMAD2/3 activity (Figure 2A, TGF-bRIIb),
whereas aActA (Figure 2A, aA c t A )a l m o s tc o m p l e t e l y
abolished SMAD2/3 activity, indicating that IL-1a and
TNF-a specifically result in secretion of Activin A from
differentiating HuSKMCs.
To directly measure the levels of Activin A protein
produced by stimulating IL-1a and TNF-a, an Activin
ELISA was used, which showed that Activin A levels
were increased by 1,152% and 459% after treatment with
IL-1a and TNF-a, respectively (Figure 2C).
To determine the signaling pathways responsible for IL-
1a- and TNF-a-induced Activin A secretion from differ-
entiating HuSKMCs, the SMAD2/3-induced luciferase
activity was analyzed, using supernatants harvested from
HuSKMCs treated with IL-1a and TNF-a, either alone or
in combination with pathway inhibitors shown to
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Figure 1 Insulin-like growth factor (IGF)-1 and ALK inhibition counteracts interleukin (IL)-1a- and tumor necrosis factor (TNF)-a-
induced inhibition of human skeletal muscle cell (HuSKMC) differentiation. (A) HuSKMC myotubes differentiated for 5 days in the absence
(Con) and presence of IL-1a (0.1 ng/ml) and TNF-a (0.1 ng/ml), alone and in combination with IGF-1 (100 nmol/l) or SB431542 (1 μmol/l), were
stained with anti-myosin heavy chain (MyHC) and DAPI. Shown are representative pictures and analysis of fusion index which was determined as
the percentage of nuclei occurring in myotubes stained with MyHC on four pictures. Data are means ± SEM from three to six independent
experiments. Differences from untreated HuSKMCs (control; first column),*P < 0.05; differences from IL-1a- and TNF-a-treated HuSKMCs (control;
second and third column), #P < 0.05. (B) Analysis of creatine kinase (CK) activity in HuSKMC myotubes differentiated for 4 days and treated with
either IL-1a (0.01-0.1 ng/ml) and TNF-a, alone (0.01 to 0.1 ng/ml) or in combination with IGF-1 (100 nmol/l) or SB431542 (1 μmol/l). Data are
expressed as percentage of control untreated HuSKMCs. Data are means ± SEM from four to nine independent experiments. Differences from
untreated HuSKMCs (control; first column),*P < 0.05; differences from IL-1a- and TNF-a-treated HuSKMCs (control; second to fourth columns), #P
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Figure 2 Interleukin (IL)-1a and tumor necrosis factor (TNF)-a induced secretion of Activin A via activation of transforming growth
factor-b-activated kinase (TAK)-1, p38 and nuclear factor (NF)B pathways during human skeletal muscle cell (HuSKMC)
differentiation. Supernatants (SNs) from HuSKMC myotubes differentiated for 3 days were analyzed in (A,B,D) HEK293Tcells stably transfected
with the SMAD-sensitive CAGA-luc reporter in a reporter-gene assay (RGA) to assess occurrence of active TGF-b proteins or (C) with Activin A
ELISA. (E) Activin A b-chain mRNA in HuSKMC myotubes differentiated for 6 hours was analyzed by reverse transcriptase (RT)-PCR. HuSKMCs
were differentiated in the absence or presence of IL-1a (0.1 ng/ml) or TNF-a (0.1 ng/ml), alone or in combination (A-C) with the neutralizing
anti-Activin A antibody (aActA), TAK-1 inhibitor, the p38 inhibitor SB203580 or the NFB inhibitor withaferin A, or (D) after small interfering (si)
RNA treatment. Data are expressed as (A,B,D) relative light units (RLU) or as percentage of control untreated HuSKMCs for (C) Activin A ELISA
and (E) RT-PCR. Data are means ± SEM from 3 to 17 independent experiments. Differences from untreated HuSKMCs,*P < 0.05; differences from
IL-1a- and TNF-a-treated HuSKMCs, #P < 0.05. (A) SNs were analyzed in CAGA-luc RGA. The soluble TGF-bRIIb/Fc chimera (500 ng/ml; TGF-bRIIb)
was added alone to the supernatant to determine the contribution of the TGF-b isoforms (TGF-b1, TGF-b2 and TGF-b3) to CAGA-luc activity or
in combination with aActA (10 μg/ml; TGF-bRIIb + aActA) to assess contribution of Activin A. (B) SNs were analyzed in CAGA-luc RGA. To
eliminate responses to the TGF-b isoforms, CAGA-luc activity was measured after addition of TGF-bRIIb to the SN. (C) SNs were analyzed with
Acitivin A ELISA. (D) SNs were analyzed in CAGA-luc RGA after addition of TGFbRIIb. SN were taken after treatment with siRNA against non-
targeting control (siNTC), Activin A b-chain (siActivin A b-chain) or SMAD2 and SMAD3 (siSMAD2/3). (E) Activin A b-chain mRNA were analyzed
by RT-PCR. Inhibitors were given 3 hours before IL-1a or TNF-a stimulation.
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Page 6 of 14modulate IL-1a and TNF-a effects. CAGA-luc activity
induced by IL-1a and TNF-a was significantly reduced by
a TAK-1 inhibitor (Figure 2B), as was Activin A level (Fig-
ure 2C), establishing a good correlation between the two
parameters. The same correlation was seen with a p38
inhibitor, SB203580, which produced a decline in both
SMAD2/3 activation (Figure 2B) and Activin A levels (Fig-
ure 2C), and an NFB inhibitor, withaferin A, (Figure 2B,
C), whereas the Jun kinase (JNK) inhibitor SP600125 did
not cause any changes (data not shown). These data sug-
gest that the IL-1a- and TNF-a-induced secretion of Acti-
vin A requires TAK-1/p38/NFBs i g n a l i n g ,b u ts e e mt o
be independent of JNK.
Genetic approaches were also used to determine the
requirement for IL-1a-a n dT N F - a-induced Activin A
expression to produce the resulting SMAD2/3 signaling.
HuSKMCs were treated before differentiation with siR-
NAs directed against either the Activin A b chain or (as
an experiment to determine where SMAD2/3 signaling
comes into play) to SMAD2 and SMAD3 (siSMAD2/3),
and then differentiated in the absence or presence of IL-
1a and TNF-a. SMAD2/3 CAGA-luc activity was ana-
lyzed after treatment with the resulting supernatant. The
siActivin A b-chain almost completely abolished
SMAD2/3 CAGA-luc responses (Figure 2D) induced by
IL-1a and TNF-a treatment of HuSKMCs, suggesting
that the observed increase in Activin A secretion is
dependent on de novo synthesis. By contrast, siSMAD2/3
inhibition of the SMAD pathway in the IL-1a-or TNF-a-
treated HuSKMCs did not alter the SMAD2/3 CAGA-luc
activity of the supernatant (Figure 2D), indicating that
activation of the ALK/SMAD2/3 pathway is downstream
of Activin A secretion. To determine the requirement for
IL-1a and TNF-a pathway stimulation for Activin A
secretion, expression of Activin A b chain was analyzed
by RT-PCR in HuSKMCs treated for 6 hours with IL-1a
and TNF-a, either alone or in combination with various
pathway inhibitors. Both IL-1a and TNF-a alone
increased expression of Activin A b-chain (Figure 2E).
These effects were not influenced by SB431542 or
aActA, but were markedly reduced by SB203580, witha-
ferin A, and TAK-1 inhibitor (Figure 2E), confirming that
IL-1a and TNF-a induce Activin A de novo synthesis via
TAK-1/p38/NFB signaling. Experiments with IL-1b
(data not shown) in HuSKMCs confirmed activation of
this TAK-1/p38/NFB pathway by IL-1b as well.
Transforming growth factor-b-activated kinase-1/p38/
nuclear factorB-dependent Activin A secretion mediates
interleukin-1a and tumor necrosis factor-a-induced
inhibition of human skeletal muscle cell differentiation,
which requires SMAD2/3
We next assessed whether Activin A secretion induced
by IL-1a and TNF-a contributes to the inhibitory effect
of these cytokines on HuSKMC differentiation. aActA
and TAK-1 (p38 and NFB inhibitors) were tested in
the presence of IL-1a and TNF-a.H u S K M C sw e r ed i f -
ferentiated in the absence or presence of IL-1a and
TNF-a, alone or in combination with aActA or inhibi-
tors. Again, IL-1a and TNF-a alone caused a marked
reduction in HuSKMC differentiation, as determined by
myotube number (Figure 3A, left panel), FI (Figure 3A,
right panel) and CK activity (Figure 3B,C). aActA pro-
moted basal HuSKMC differentiation (by up to 80%)
and partially rescued it from the inhibitory effects of IL-
1a and TNF-a as determined either by FI (Figure 3A,
right panel) or CK activity (Figure 3B) showing that
inhibition of differentiation by IL-1a and TNF-a
requires Activin A secretion. TAK-1 inhibitor (Figure
3A, right panel; Figure 3B), p38, SB203580 (Figure 3B)
and the NFB inhibitor withaferin A (Figure 3B) all
tended to rescue differentiation from the inhibitory
effects of IL-1a and TNF-a, confirming the requirement
of TAK-1/p38/NFB signaling on blockade of differen-
tiation. In fact, SB203580 and withaferin A increased
basal CK activity by up to 81% and 32%, respectively
(Figure 3B) confirming the contribution of endogenous
p38/NFB signaling to the basal tone of HuSKMC
differentiation.
Genetic inhibition with siActivin A b-chain and siS-
MAD2/3 treatment also increased CK activity, by up to
54% and 94%, respectively, and rescued it from rescued
it from the inhibitory effects of IL-1a and TNF-a (Fig-
ure 3C). These data confirm the dependence of IL-1a-
and TNF-a-mediated inhibition of differentiation on the
induction of Activin A de novo secretion and subse-
quent activation of ALK/SMAD signaling.
Interleukin-1a and tumor necrosis factor-a signal via
transforming growth factor-b-activated kinase-1 p38/
nuclear factor B and subsequently Activin A/SMAD2/3/
AKT in differentiating human skeletal muscle cells
Signaling experiments were performed in differentiating
HuSKMCs, using either analysis of NFB activity (Figure
4A) or western blotting (Figure 4B,C) to determine the
contributing pathways required for Activin A release.
NFB signaling was assessed by an adenoviral NFb-
Luciferase reporter. The NFB CAGA-luc activity
induced by IL-1a and TNF-a was counteracted by
TAK-1 inhibitor and by withaferin A (Figure 4A) indi-
cating that TAK-1 is involved in IL-1a and TNF-a acti-
vation of NFB signaling and, thus is upstream of
NFB. However, TAK-1 inhibitor was less efficacious
than withaferin in blocking NFB signaling, indicating
only partial NFB inhibition by TAK-1.
We next analyzed HuSKMCs stimulated with IL-1a
and TNF-a, either alone or in combination with TAK-1
inhibitor, using phospho-specific antibodies for signaling
Trendelenburg et al. Skeletal Muscle 2012, 2:3
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Figure 3 Inhibition of human skeletal muscle cell (HuSKMC) differentiation by interleukin (IL)-1a and tumor necrosis factor (TNF)-a is
mediated by transforming growth factor-b-activated kinase (TAK)-1/p38/nuclear factor (NF)B/Activin A/SMAD2/3 pathway. (A) HuSKMC
myotubes differentiated for 5 days in the absence (Con) and presence of IL-1a (0.1 ng/ml) or TNF-a (0.1 ng/ml), alone and in combination with the
neutralizing neutralizing anti-Activin A antibody (10 μg/ml; aActA) or TAK-1 inhibitor (1 μmol/l) were stained with anti-myosin heavy chain (MyHC) and
DAPI. Shown are representative pictures and analysis of fusion index, which was determined as the percentage of nuclei occurring in myotubes
stained with MyHC on four pictures taken. Data are means ± SEM from four to six independent experiments. Differences from untreated HuSKMCs
(control; first column),*P < 0.05; differences from IL-1a-a n dT N F - a-treated HuSKMCs (control, second and third column), #P < 0.05. (B) Analysis of CK
activity from in HuSKMC myotubes differentiated for 4 days and treated with either IL-1a (0.01-0.1 ng/ml) and TNF-a alone (0.01-0.1 ng/ml), and in
combination with aActA (10 μg/ml), TAK-1 inhibitor (1 μmol/l), SB203580 (10 μmol/l) or withaferin A (100 nmol/l). Data are expressed as percentage of
control from untreated HuSKMCs. Data are means ± SEM from three to nine independent experiments. Differences from untreated HuSKMCs (control;
first column),*P < 0.05; differences from IL-1a- and TNF-a-treated HuSKMCs (control, second to fourth columns), #P < 0.05. (C) Analysis of CK activity
from in HuSKMC myotubes differentiated for 4 days and treated with IL-1a (0.01-0.1 ng/ml) and TNF-a alone (0.01-0.1 ng/ml) after treatment with
either small interfering (si)RNA against non-targeting control (siNTC), siActivin A b-chain or siSMAD2/3. Data are means ± SEM from five to seven
independent experiments. Differences from siNTC-treated HuSKMCs (siNTC; first column),*P < 0.05; differences from IL-1a-a n dT N F - a-treated
HuSKMCs (siNTC, second to fourth columns), #P < 0.05.
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Figure 4 Inhibition of human skeletal muscle cell (HuSKMC) differentiation by interleukin (IL)-1a and tumor necrosis factor (TNF)-a is
mediated by the transforming growth factor-b-activated kinase (TAK)-1/p38/nuclear factor (NF)B/Activin A/SMAD2/3 pathway. (A) Analysis
of NFB-luc assay (RGA) from HuSKMC myoblasts treated with IL-1a (1 ng/ml) and TNF-a (1 ng/ml) alone, and in combination with TAK-1 inhibitor
(0.1-1 μmol/l) or withaferin A (0.1-1 μmol/l). Data are expressed as relative light units (RLU). Data are means ± SEM from four independent experiments.
Differences from IL-1a-a n dT N F - a-treated HuSKMCs (first column),*P < 0.05. (B) Immunoblotting of phospho-TAK-1, phospho-SEK1/MKK4, phospho-
p38MAPK, phospho-c-Jun, phospho-ATF2, phospho-NFB, phospho-SMAD2 and phospho-SMAD3 of samples from HuSKMCs treated with TNF-a (0.1
to 10 ng/ml) or IL-1a (0.1 to 10 ng/ml) for 15 minutes alone, and in the presence of TAK-1 inhibitor (1 μmol/l) starting at the onset of differentiation.
The TAK-1 inhibitor was given 3 hours before IL-1a or TNF-a stimulation. Shown are representative immunoblots. (C) Immunoblotting of phospho-
SMAD2, phospho-SMAD3 and pAKT of samples from HuSKMCs treated with TNF-a (0.1 to 10 ng/ml) or IL-1a (0.1 to 10 ng/ml) for 24 hours, alone and
in the presence of SB431542 (1 μmol/l), aActA (10 μg/ml), TAK-1 inhibitor (1 μmol/l), SB203580 (10 μmol/l) or withaferin A (300 nmol/l) starting at the
onset of differentiation. Inhibitors were given 3 hours before IL-1a or TNF-a stimulation. Shown are representative immunoblots.
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Page 9 of 14molecules (Figure 4B). Both IL-1a and TNF-a (and IL-
1b; data not shown) increased phosphorylation of TAK-
1 ,M K K 4 ,p 3 8 ,c - J u n ,A T F 2 ,N F B, and p65 in a con-
centration-dependent manner (Figure 4B). TAK-1 inhi-
bitor markedly reduced phosphorylation by IL-1a and
TNF-a (Figure 4B), indicating that TAK-1 is upstream
of NFB, MKK, p38, c-Jun, and ATF2. By contrast,
SMAD2/3 phosphorylation remained unchanged by this
short treatment with IL-1a and TNF-a (Figure 4B), in
agreement with the observation that immediate Activin
A secretion is independent of SMAD2/3, but secreted
Activin A subsequently signals through SMAD2/3.
To further test this model, HuSKMCs stimulated for
24 hours with IL-1a and TNF-a, alone or in combina-
tion with various inhibitors, were analyzed. Secreted
activin A after 24 hours of treatment was assessed by
measuring TGF-b CAGA-luc activity from supernatants
(data not shown). At this later time point, both IL-1a
and TNF-a resulted in an increase in phosphorylation
of SMAD3, but SMAD2 was increased only marginally,
and only upon IL-1a stimulation (Figure 4C). In addi-
tion, there was a decrease in phosphorylation of AKT
(Figure 4C) which has been previously shown to be a
consequence of ALK/SMAD(2)/3 signaling in skeletal
muscle cells (Figure 4C). Therefore, AKT inhibition is
another indicator of cytokine-mediated induction of
Activin A signaling. SMAD(2)/3 phosphorylation was
counteracted by SB431542, aActA, TAK-1 inhibitor,
SB203580 and withaferin A (Figure 4C). Inhibition of
AKT phosphorylation was also counteracted by
SB431542, aActA, and TAK-1 inhibitor, whereas
SB203580 and withaferin A were not as effective (Figure
4C).
Taken together, these results further support the
model that IL-1a and TNF-a cause Activin A secretion
via TAK-1/p38/NFB signaling, and that secreted activin
A subsequently signals in an autocrine fashion via ALK/
SMAD(2)/3/AKT to inhibit differentiation (Figure 6).
The transforming growth factor-b-activated kinase-1/p38/
Activin A/SMAD3 signaling pathway is upregulated in rat
sarcopenia
Sarcopenia (the loss of skeletal muscle associated with
advanced age) has been reported to be due in part to
impaired muscle-cell differentiation [3]. Therefore, we
analyzed muscle samples from rats of different ages, to
s e ei fc y t o k i n ei n d u c t i o no fA c t i v i nAa n di t sd o w n -
stream pathway might contribute to sarcopenia (Figure
5A,B). phospho-SMAD3 significantly increased by up to
5.8-fold between the ages of 6 and 24 months in rat
muscle. Similarly, phospho-TAK-1 and phospho-p38
were significantly increased at 24 months, by up to 2.4-
and 3.1-fold, respectively. By contrast, GAPDH protein
levels were similar at all ages. Expression of Activin A
b-chain (Figure 5B) increased with age by up to 4.8-fold,
and serum TNF-a levels also increased (data not
shown), confirming upregulation of the TNF-a/TAK-1/
p38/Activin A/SMAD3 pathway during aging.
Conclusions
In this study, we found that IL-1a and TNF-a inhibited
the differentiation of human myoblasts, and that this
inhibition was mediated by the induction of Activin A
signaling (Figure 6). The result is an interesting instance
of inflammatory cytokine-induced crosstalk, stimulating
TGF-b-type signaling. The induction of Activin A secre-
tion downstream of cytokine pathway stimulation sug-
gests a mechanism explaining how cytokines perturb
muscle differentiation, because it is well established that
TGF-b family members such as myostatin and Activin
A can block myoblast differentiation [8,13,42,43]. The
inhibition of differentiation by IL-1a and TNF-a was
significant, being at least 50%, and as much as 100%, as
measured by FI or CK activity.
The stepwise nature of the cytokine pathway activa-
tion leading to Activin A secretion and subsequent
SMAD activation was shown using both pharmacologi-
cal and genetic tools. First, we determined, using a
direct measurement of Activin A via an ELISA. that
there is a 7- to 10-fold induction of Activin A levels in
the supernatants of myoblasts after treatment with the
inflammatory cytokines IL-1a and TNF-a The selectiv-
ity of the induction was shown using a blocking anti-
body to Activin A, which was able to ablate the
induction of SMAD2/3 signaling caused by the cyto-
kines, as opposed to the soluble TGF-b receptor trap,
which had no effect.
W ef o u n dt h a ti n d u c t i o no fA c t i v i nAr e s u l t e di na n
activation of downstream Activin receptor signaling, via
the SMAD2/3 transcription factors, because blockade of
Activin A using the neutralizing antibody ablated the
IL-1a/TNF-a-induced SMAD2/3 response.
The signaling cascade downstream of TNF-a and IL-1a
which resulted in Activin A stimulation, was also deter-
mined (Figure 6). We found that TAK-1 activation is
required for Activin A secretion, because an inhibitor to
TAK-1 blocked the increase in Activin A, and rescued
myoblast differentiation. As expected, TAK-1 blockade
also inhibited the downstream activation of p38, which is
also required for Activin A production, as shown by
assessment of SMAD2/3 signaling in cells treated with or
without a p38 inhibitor; p38 blockade increased myoblast
differentiation. In contrast to the results with p38, inhibi-
tion of JNK did not perturb Activin A signaling, establish-
ing the specificity of the TAK-1/p38 pathway. NFBa l s o
contributed to Activin A induction, although p38 inhibi-
tion had a much greater effect than NFB in rescuing dif-
ferentiation and in blocking SMAD2/3 activation (Figure
Trendelenburg et al. Skeletal Muscle 2012, 2:3
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Page 10 of 146). This pathway was also seen in HuSKMCs for IL-1b,
another native pro-inflammatory cytokine acting on IL-1
receptors (data not shown).
There has been some debate in the literature as to
whether inflammatory cytokines play a negative or positive
role on myoblast differentiation into myotubes. Although
it is still possible that there may be a positive role at low
concentrations and particular time points, in this study the
effect of the cytokines was convincingly anti-differentia-
tion, bolstered by the dramatic induction of an established
mechanism for the inhibition of myoblast differentiation.
The induction of Activin A by TNF-a and IL-1a may help
to explain some of the phenotypes previously reported in
aging animals, including humans. There are multiple
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Figure 5 Transforming growth factor-b-activated kinase (TAK)-1/p38/Activin A/SMAD3 pathway activation in a rat sarcopenia model.
(A) Immunoblotting of phospho-SMAD3, phospho-TAK-1, phospho-p38 and GAPDH in samples from rats of different ages. The gastrocnemius
muscle was sampled from four rats per age point (6, 18, 12 and 24 months). Shown are representative immunoblots and averaged densitometry
data from the blots. (B) Analysis of Activin A b-chain mRNA taken from rat gastrocnemius muscle. Data are expressed as percentage of control
(first column, 6-month-old rats) and shown as means ± SEM from four individual rats. Differences from control (first column, 6-month-old rats),*P
< 0.05.
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Page 11 of 14reports that inflammatory signaling goes up as mammals
age, coincident with the onset of sarcopenia [44]. In addi-
tion, it has been shown that there is an increase in TGF-b
in sarcopenic animals [45]. The data in this study demon-
strate that TNF-a/TAK-1/p38/SMAD/Activin A signaling
increases coordinately with age, and that this is not a coin-
cidence, but rather cause and effect.
Inflammatory cytokines and the resultant activation of
the NFB pathway have been previously shown to
induce skeletal muscle atrophy in differentiated muscle,
by activating the E3 ubiquitin ligase, MuRF1 [46]. This
study establishes the mechanism for an additional anti-
muscle effect of cytokines: the blockade of differentia-
tion by Activin A secretion. The data suggest that treat-
ment of sarcopenia with agents that block the relevant
cytokines that activate TAK-1 would not only block the
established pro-atrophy effects of NFB, but would also
provide an upstream inhibition of Activin A release,
effectively shutting down two pathways that negatively
perturb skeletal muscle in sarcopenia and cachexia.
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